Loading viewer...
earnings
Format: PDF earnings
Telix Pharmaceuticals' H1 2024 interim results presentation delivered on 22 August 2024. The presentation covers financial and operational achievements for the first half of 2024, including updates on the company's lead product Illuccix® for prostate cancer imaging, which has received regulatory approvals in Australia, the United States, and Canada.
annual_report
14 Pages
earnings
32 Pages
Unknown
Bumrungrad Hospital 2Q22 2022 Investor Presentation Results
earningsearnings
50 Pages
Bumrungrad Hospital Public Company Limited
ICE Second Quarter First Half 2016 Earnings
earningsearnings
23 Pages
Intercontinental Exchange
UltraTech Cement Q3 FY23 Results 2023
earningsearnings
27 Pages
UltraTech Cement